Related Experiment Video
Updated: May 27, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression]
Kai Sun1, Wei Wang, Shang-tong Lei
1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. sunkai9602@sina.com
Objective:
To investigate the regulatory effect of microRNA-221 (MIR221) on CDKN1C/p57 expression in colon carcinoma cells in vitro.
Methods:
Caco2 cells were treated with or without anti-p57-siRNA prior to the addition of pre-MIR221 or anti-MIR221. The MIR221 expression pattern was detected by real-time RT-PCR, and the mRNA and protein levels of CDKN1C/p57 expression were detected using semi-quantitative RT-PCR and Western blotting. Caco2 cell proliferation following the treatment was detected with MTT assay. CDKN1C/p57 3'-UTR fragment was amplified by PCR from the genome DNA of human colon and inserted into a luciferase reporter plasmid. The luciferase reporter plasmid construct was then transfected into Caco2 cells along with pre-MIR221 or anti-MIR221, and the luciferase activity in the transfected cells was detected.
Results:
MIR221-specific inhibitor significantly up-regulated CDKN1C/p57 protein expression in Caco2 cells (P<0.01). Anti-MIR221 could markedly inhibit Caco2 cell proliferation, and the inhibitory effect was obviously abolished by pretreatment with anti-p57-siRNA, suggesting that the inhibition was mediated by CDKN1C/p57 (P<0.01). A significant increase of luciferase activity was detected in Caco2 cells co-transfected with the luciferase reporter plasmid construct and anti-MIR221 (P<0.01).
Conclusions:
MIR221 can interact with the target site on the 3'-UTR of CDKN1C/p57 mRNA to inhibit CDKN1C/p57 expression by post-transcriptional gene silencing to promote colon carcinoma cell proliferation, suggesting the value of MIR221 as a potential target for treatment of colon carcinoma.
Insights
MicroRNA-221 (MIR221) inhibits CDKN1C/p57 expression, promoting colon cancer cell growth. Targeting MIR221 may offer a new therapeutic strategy for colon carcinoma.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Context:
- Colon carcinoma is a significant global health concern.
- MicroRNAs play crucial roles in cancer development and progression.
- Understanding gene regulation in cancer cells is vital for therapeutic development.
Purpose:
- To investigate the regulatory role of microRNA-221 (MIR221) on CDKN1C/p57 expression in colon carcinoma cells.
- To elucidate the mechanism by which MIR221 affects colon cancer cell proliferation.
- To assess the potential of MIR221 as a therapeutic target in colon cancer.
Summary:
- MIR221 was found to directly interact with the 3'-UTR of CDKN1C/p57 mRNA, leading to its post-transcriptional silencing.
- Inhibition of MIR221 significantly increased CDKN1C/p57 expression and suppressed colon cancer cell proliferation.
- Luciferase reporter assays confirmed the direct interaction between MIR221 and CDKN1C/p57.
- The study demonstrates that MIR221 promotes colon carcinoma cell proliferation by downregulating CDKN1C/p57.
Impact:
- This research identifies MIR221 as a key regulator of CDKN1C/p57 in colon cancer.
- The findings suggest that MIR221 is a potential therapeutic target for colon carcinoma treatment.
- This study contributes to the understanding of microRNA-mediated gene regulation in cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
